|
|
|||
 |
BioPortfolio Bulletin | ||
| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_43.htm June 15 2004 | ||
|
| |||
Lead Sponsor:
|
Biotech industry
expert Dr. Ron Garren analyzes newsworthy events in the medical
marketplace and places them in the context of value to the investor.
Through his website, he distributes frequent email alerts to subscribers.
An archive of past alerts, along with a model portfolio of biotech stocks
is also available. http://www.biotechinsight.com/ |
||
|
|
|||
|
In this Week's issue: 1) Biotech industry expert Dr. Ron Garren analyzes newsworthy events - see above 2) The Pharmaceutical CRM Outlook: Optimizing returns from operational and analytical CRM 3) Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook 4) Biotechnology Management Practices - get your management right to prosper! 5) The Technology Web - Database of 1916 service providers, including 581 subsidiaries, in 49 countries 6) BioAnnouncement - view examples Cytomyx & Guava Technologies
|
|||
|
|
|||
| The Pharmaceutical CRM Outlook: Optimizing returns from operational and analytical CRM | |||
|
|
A new strategic management report from Reuters Business Insight The new Reuters Business Insight report: ‘The Pharmaceutical CRM Outlook: Optimizing returns from operational and analytical investment’ analyzes the current operational and analytical CRM practises and outlines in detail the future developments that will increase the return on investment (ROI) within sales, marketing and customer fulfillment activities. Improve your sales force effectiveness, maximize product usage and drive up your ROI with the help of this latest report… Top three reasons why this is a 'must have' report this month: Secure the most profitable customers and capitalize on CRM's potential to increase your customer's propensity to purchase products or services at a lowered cost of transaction. Reduce set-up time and costs of CRM experimentation by learning from the industry leaders' best practice such as Roche, AstraZeneca and Merck. Utilize technology-based solutions to increase the ROI from physician detailing and assess the viability of newer technologies, such as voice recognition and iTV. Reuters Business Insight reports are published by Datamonitor, in association with Reuters. Reuters, the sphere logo and Reuters Business Insight are trade marks of the Reuters group of companies around the world and are used by Datamonitor under licence from Reuters. http://www.bioportfolio.com/cgi-bin/acatalog/Reuters_Business_Insight_2004.html#a611
|
||
| Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook | |||
|
The global market for Monoclonal Antibody (Mab)
Therapeutics reached a total of $7.2 billion in 2003. The market has been
growing at an impressive compound average annual growth rate of 53% over
the previous five years.
The key advantage of Mab Therapeutics is their high levels of specificity for the relevant disease targets. This pinpoint specificity also serves to prevent harm to healthy cells and, hence, typically results in fewer adverse effects compared to other medicines. Many of the leading pharmaceutical companies have entered the MAb sector, attracted by quicker and less costly development, higher success rates, premium pricing, and a potentially reduced threat from generics. |
||
| Biotechnology Management Practices | |||
|
Mardis Aibel have performed a unique study:
Most business executives would argue that companies lacking basic management skills are unlikely to succeed in the marketplace or generate significant returns for shareholders. Nevertheless, both managers and investors in numerous biotechnology firms seem to believe that this standard wisdom does not hold true for them. Research completed last year by Mardis, Aibel & Associates shows that a substantial portion of biotech executives view “achieving operational excellence” as a secondary concern. Many report that a significantly higher priority is “validating the scientific concept”, “searching for funding” or “publicizing the work of the firm”. Similarly, many biotech investors quietly acknowledge that they care less about creating firms with viable management models than in pushing firms to the next news announcement that will drive a jump in valuation. The all-too-common belief for many in the industry is that, for biotech's, first-class management is not needed to achieve world-class returns. They are wrong. For more information open:
|
||
| The Technology Web® | |||
|
|
> Database of 1916
service providers, including 581 subsidiaries, in 49 countries
> Categorised by 21 services such as in the area of chemistry, pre-clinical biology, pharmaceutics, safety, and clinical development > Details of company or institution address, telephone, fax, web and e-mail address, as well as company contact field > Used by Arachnova in combination with knowledge of outsourcing market and experience of outsourcing management for provider selection > Provided to third parties through the web. To evaluate (limited searching for free) click Technology Web Trial http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_Arachnova_13.html |
||
| BioAnnouncements - promoting technology to the life science sector | |||
|
Do you have technology that you wish to license?
Do you want to contact 50,000 life science users? Complete the online enquiry form - click here! View examples: |
In 2004, LeadDiscovery & BioPortfolio, two of the largest drug development information providers combined their resources to launch BioAnnouncements. Through this service, LeadDiscovery distributes dedicated mail shots announcing licensing opportunities and R&D services to the drug discovery community. Interested? Email: leaddiscovery@leaddiscovery.co.uk Read more: http://www.leaddiscovery.co.uk/adpage.html
|
||
|
Contact
us:
To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove
your email address from the list based on your email
address. If your email has changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually
unsubscribe for you. Thank you for your understanding.
©2004 BioPortfolio Limited | |||
|
| |||
